TipRanks | Stock Market Research, Analysis, News & Investing Tools
RedHill Biopharma ($RDHL) is making a bold move in the GI space. The company just secured exclusive global rights to two FDA-approved gastrointestinal drugs - Rebyota and Clenpiq - from Ferring Pharmaceuticals. The kicker? These drugs pulled in ~$37.5M in combined 2025 US sales, and RedHill paid just $12M upfront, funded entirely by its recent sale of its Talicia business. Rebyota is the first and only single-dose treatment approved to prevent recurrent C. diff infection, a serious bacterial infection affecting millions worldwide each year. Clenpiq is a widely-used bowel prep drug. CEO Dror Ben-Asher called it a "clear strategic sequence" - and with the global GI therapeutics market projected to grow to $51.5B by 2033, this deal could position RedHill for further growth. Read the full breakdown on TipRanks: https://www.tipranks.com/news/redhill-biopharma-pushes-for-growth-securing-rights-to-ferrings-37m-gastrointestinal-drugs-portfolio #RedHillBiopharma #RDHL #Biotech #Pharma #StockNews #Investing #TipRanks #BiotechStocks
single adCTA: Saber mais